Welcome to our dedicated page for Innate Pharma Marseille SEC filings (Ticker: IPHYF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Innate Pharma S.A. (IPHYF) SEC Filings provides access to the company’s regulatory disclosures as a foreign private issuer. Innate Pharma S.A. reports to the U.S. Securities and Exchange Commission using Form 20-F and submits Form 6-K current reports that often include press releases as exhibits, such as those dated in September 2025.
On this page, you can review Innate Pharma S.A.’s 6-K and related filings as they are made available through the SEC’s EDGAR system. These documents include current reports that reference press releases, along with detailed financial and structural information prepared under IFRS, covering items such as ordinary and preference shares, issued capital, share premium, retained earnings, accumulated other comprehensive income, and various categories of shareholders.
Filings also describe assets and financing arrangements, including licences, intangible assets under development, land and buildings, laboratory equipment, construction in progress, and right-of-use assets. The disclosures reference loan agreements and lease financing obligations, such as a PGELoanAgreement with Societe Generale and BNP Paribas, and lease obligations for buildings, premises, equipment, vehicles, printers, and other assets.
Stock Titan enhances these filings with AI-powered summaries that help explain the structure and content of lengthy regulatory documents. Users can quickly identify key sections in Innate Pharma S.A.’s 6-K and other filings, see how capital structure and financing are presented, and locate information related to shareholders and counterparties, all without reading every line of the original text.
FAQ
What is the current stock price of Innate Pharma Marseille (IPHYF)?
